Dianthus Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a DNTH research report →
About the company
Dianthus Therapeutics, Inc. , a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function.
- CEO
- Marino Garcia
- IPO
- 2018
- Employees
- 92
- HQ
- New York, NY, US
Price Chart
- Market Cap
- $3.94B
- P/E
- -857.64
- P/S
- 2948.13
- P/B
- 3.77
- EV/EBITDA
- -304.95
- Div Yield
- 0.00%
- Gross Margin
- 94.31%
- Op Margin
- -14318.04%
- Net Margin
- -847.53%
- ROE
- -1.78%
- ROIC
- -15.82%
- Revenue
- $2.04M · -67.35%
- Net Income
- $-162,337,000 · -91.05%
- EPS
- $-4.20 · -64.71%
- Op Income
- $-177,933,000
- FCF YoY
- -65.13%
- 52W High
- $98.70
- 52W Low
- $17.88
- 50D MA
- $86.79
- 200D MA
- $60.15
- Beta
- 0.09
- Avg Volume
- 898.72K
Get TickerSpark's AI analysis on DNTH
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 17, 26 | Veness Adam M | other | 30,000 |
| Jun 17, 26 | Veness Adam M | other | 30,000 |
| Jun 17, 26 | Veness Adam M | sell | 16,771 |
| Jun 17, 26 | Veness Adam M | sell | 13,229 |
| Jun 1, 26 | Randhawa Simrat | other | 9,375 |
| Jun 1, 26 | Randhawa Simrat | other | 6,908 |
| Jun 1, 26 | Randhawa Simrat | other | 6,249 |
| Jun 1, 26 | Randhawa Simrat | other | 9,375 |
| Jun 1, 26 | Randhawa Simrat | sell | 5,428 |
| Jun 1, 26 | Randhawa Simrat | other | 6,249 |
Our DNTH coverage
Recent articles, reports, and earnings notes.
No research on DNTH yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate DNTH report →Similar companies
Peers in the same neighborhood.